background: Balanced chromosomal rearrangements represent one of the most frequent indications for preimplantation genetic diagnosis (PGD). Although fluorescence in situ hybridization (FISH) has been successfully employed for diagnosis in such cases, this approach usually restricts assessment of the chromosomes involved in the rearrangement. Furthermore, with FISH-based strategies, it is sometimes necessary to create patient-specific protocols, increasing the waiting time and costs. In the current study, we explored the use of two comprehensive chromosome screening methods, conventional metaphase comparative genomic hybridization (CGH) and microarray-CGH (aCGH), as alternatives for PGD of chromosome rearrangements.
Introduction
Balanced chromosomal rearrangements, such as translocations and inversions, represent a relatively common form of genetic abnormality. The frequency in prenatal samples and newborns has been determined to be 0.4 and 0.19%, respectively (Jacobs et al., 1974; Van Dyke et al., 1983; reviewed in Simpson and Bischoff, 2002) . In most cases, balanced chromosome rearrangements do not cause any problems for the carrier, until they attempt to have children. At this point, it is common to observe decreased fertility, high rates of miscarriage and in some cases, the birth of children affected by congenital abnormalities and/or mental retardation. These problems are due to the abnormal segregation of rearranged chromosomes at meiosis, leading to the production of large numbers of gametes with extra or missing regions of the genome.
While the incidence of chromosomal rearrangements is appreciable in the population at large, they are even more common among infertile patients. In the case of couples undergoing IVF treatment with a history of recurrent miscarriages or repeated IVF failure, the frequency of chromosomal rearrangements is 25-fold higher (5%) than that found in the general population (Campana et al., 1986; Frynes and Buggenhout, 1998; Stern et al., 1999) . For these infertile patients, the high prevalence of gametes that have lost or gained chromosome material as a result of the rearrangement is likely to be the single most significant factor in their previous pregnancy losses and lack of IVF success (reviewed in Scriven et al., 1998) .
Preimplantation genetic diagnosis (PGD) can be used as a tool to assist in the identification and transfer of chromosomally normal or balanced embryos produced using assisted reproductive technologies (ARTs). As PGD ensures that the only embryos transferred are those with an appropriate amount of DNA from the rearranged chromosomes, the risk of miscarriage or the birth of affected children is greatly reduced. Since the first PGD cases for translocations, reported in 1998, the principal method used to distinguish chromosomally balanced embryos from those that are unbalanced has been fluorescence in situ hybridization (FISH) (Conn et al., 1998; Munne et al., 1998 Munne et al., , 2000 Escudero et al., 2001 Escudero et al., , 2003 Simopoulou et al., 2003; Sampson et al., 2004; Otani et al., 2006; Lim et al., 2008; Fischer et al., 2010) . Strategies for PGD based upon FISH have proved highly effective, resulting in hundreds of successful cycles. However, these approaches are not without shortcomings.
The most obvious limitation of FISH-based tests is that they are unable to provide a comprehensive cytogenetic evaluation. In most cases, analysis is restricted to the chromosomes involved in the rearrangement. While these remain the chromosomes at the highest risk of producing an abnormality, there is also a significant risk of de novo abnormalities affecting other chromosomes. These are not caused by the rearrangement, but are associated with other factors, most notably advancing maternal age (e.g. trisomy 21). Ideally, a PGD test would be able to detect these forms of aneuploidy as well as imbalance related to the chromosome rearrangement.
An additional problem is that carriers of reciprocal translocations and inversions usually have unique rearrangements, necessitating the creation of personalized protocols for each couple before the PGD case. The design and validation of such individualized tests delays treatment and adds to the expense of the procedure. For reciprocal translocations, the need for patient-specific protocols has been somewhat reduced by the commercial availability of subtelomeric probes, but in some cases considerable preclinical optimization and testing may still be necessary (Harton et al., 2010) . Another limitation of the FISH approach is that it is dependent on fixation of a single cell on a microscope slide, which is a procedure that requires skill and experience, and may be associated with diagnostic problems (e.g. overlapping or split signals) (reviewed in Wells et al., 2008) .
Molecular strategies have also been used to detect chromosome imbalances in embryos derived from carriers of chromosome rearrangements. PCR-based protocols utilizing informative short tandem repeats (STRs) on both segments of the translocated chromosomes have been reported and their use has resulted in ongoing pregnancies and deliveries of healthy babies (Fiorentino et al., 2010; Traversa et al., 2010) . This approach overcomes some of the technical limitations of FISH and offers the advantage of tracking the inheritance of individual chromosomes, improving the interpretation of segregation outcomes and allowing the detection of uniparental disomy. The main limitations of PCR-based methods are that work-up is necessary prior to any clinical case in order to establish which STR polymorphisms are informative, and the number of chromosomes assessed remains limited (usually, only the chromosomes involved in the translocation are assessed).
Comparative genomic hybridization (CGH) is a molecular cytogenetic method that allows comprehensive chromosome screening. CGH has been successfully applied to the preimplantation genetic screening (PGS) of polar bodies (PBs) (Wells et al., 2002; Fishel et al., 2010; Fragouli et al., 2010) , cleavage-stage embryos (Voullaire et al., 2002; Wilton et al., 2003) and blastocysts, with promising clinical outcomes Fragouli et al., 2010; Schoolcraft et al., 2010) . As well as detecting aneuploidy affecting whole chromosomes, CGH is also capable of identifying losses and gains of chromosome segments and should, therefore, be capable of detecting imbalances caused by a wide variety of chromosome rearrangements (Voullaire et al., 2000; Wells and Delhanty, 2000; Fragouli et al., 2006a Fragouli et al., , 2010 Alfarawati et al., 2011) . However, up until now there has been only one study that has applied CGH to embryos produced by a carrier of a chromosome rearrangement. In that case, the embryos had already been diagnosed using standard FISH, and CGH was only used for re-analysis of embryos that were not transferred (Malmgren et al., 2002) . More recently, microarray-CGH (array CGH or aCGH) has been introduced, which provides results similar to CGH but in a more rapid timeframe (Gutiérrez-Mateo et al., 2010) .
Here, we report the first births achieved following PGD of chromosome rearrangements using comprehensive screening of all the chromosomes via CGH or aCGH applied to PBs, cleavage-stage embryos and blastocysts. Not only do these approaches allow the detection of unbalanced products from multiple chromosomal rearrangements using a single protocol, but they also reveal coincident aneuploidy involving chromosomes unrelated to the rearrangement.
Materials and Methods
Notes on microarrays used, patient details and embryo biopsy All patients with structural chromosomal rearrangements, at risk of producing abnormal gametes leading to miscarriages or abnormal offspring and desiring to undergo PGD, were assessed by a cytogeneticist. Cases that had rearranged segments larger than 2 Mbp were included. The sensitivity of the high-resolution microarray (CytoChip Version 3.0, BlueGnome, Cambridge, UK) applied to single cells is 2 -5 Mbp depending on where within the genome the rearrangement is situated. The manufacturer supplies software with their latest microarray product (24Sure+, BlueGnome), which calculates the likelihood of detecting a segmental chromosome imbalance with specified breakpoints. The smallest fragment detected in the current study was 2.8 Mbp in size using the CytoChip Version 3.0 microarray. The minimum number of microarray probes used to diagnose loss or gain of a chromosomal fragment was 15 probes, although in most cases chromosome rearrangements affected a greater number of probes. In the case of conventional CGH, we have detected unbalanced fragments smaller than 5 Mbp in previous studies. However, microarrays are considered to have superior resolution and are preferred for any rearrangement involving fragments ,10 Mbp in size.
The data presented were derived from 20 PGD cycles for 16 patients carrying a variety of chromosome rearrangements. The average maternal age was 36.3 years (maternal age range 31 -43), and the chromosome rearrangements included five carriers of Robertsonian translocations, nine carriers of reciprocal translocations and three carriers of inversions (for one couple, the male partner was a carrier of a reciprocal translocation and the female partner was a carrier of an inversion) (Table I) . In a single case, our diagnostic laboratory had not been informed that one of the patients was a carrier of an inversion, as the referring laboratory had assumed that this would not be detectable. In this instance, the patients had requested general aneuploidy screening without specific reference to the rearrangement.
Diagnosis was performed at a variety of different preimplantation stages: for nine of the cases, trophectoderm cells (TEs) biopsied from Day-5/-6 blastocysts (61 blastocysts, 5 cells biopsied from each embryo) were tested; three cases assessed first and second PBs (25 first + 25 second PBs) and eight cases tested blastomeres biopsied from Day-3 embryos (46 embryos, one cell from each embryo). The diagnosis was performed using conventional metaphase CGH for 9 cases (6 cases on TE samples and 3 cases on first and second PBs) and 11 using aCGH [(8 cases on blastomeres, 5 using 24Sure Version 2.0 microarrays, screening resolution of 10 Mbp (BlueGnome) and 3 using the higher resolution CytoChip Version 3.0 microarrays with a screening resolution 2 -5 Mbp depending on where the aberration was within the genome (BlueGnome) and 3 cases on TE cells using CytoChip Version 3.0 microarrays (BlueGnome)]. All biopsies involved breach of the zona pellucida with a laser, regardless of the embryonic stage being tested. Specific details of stimulation, biopsy and embryo culture varied between the referring clinics, but did not differ significantly from methods considered to be standard. Embryos tested at the blastocyst stage were vitrified after biopsy to allow time for CGH analysis. Euploid embryos were warmed and transferred in a subsequent cycle .
All IVF centres involved in this study had the necessary ethical and clinical approvals and licenses required for the tests offered to patients. All patients were provided with counselling regarding PGD and PGS using CGH or aCGH, and signed consent was obtained in all cases.
Comparative genomic hybridization
The protocols used for processing biopsied cells and the validated CGH method were performed as described by Wells et al. (1999) , with modifications (Fragouli et al., 2006b . CGH was used to diagnose TEs and PBs. Briefly, biopsied cells were lysed and their DNA amplified using degenerate oligonucleotide-primed PCR (DOP-PCR). The resulting DNA was subjected to nick translation, allowing nucleotides labelled with a green fluorochrome to be incorporated. DNA from a chromosomally normal individual was similarly amplified and labelled with a red fluorochrome. The two DNAs were mixed and then applied to normal metaphase chromosomes on a microscope slide. Red and green DNA fragments hybridized to each chromosome, producing fluorescence (i.e. green:red ratio) proportional to the number of copies of the target regions in the embryo cell sample. Target regions with a green:red ratio of ≥1.2 were considered to be present in excess (e.g. trisomy), while those with a ratio of ≤0.8 were considered to have been lost (e.g. monosomy or nullisomy).
The resolution of CGH on single cells is around 10 Mbp (Malmgren et al., 2002) , although our previous experience suggests that unbalanced fragments as small as 5 Mbp can usually be detected. The accuracy rate for CGH has been reported to be around 87% for PBs and 93.2% for trophectoderm biopsy. CGH was able to detect aneuploidies in a blastocyst biopsy when it was present in ≥30% of the biopsied samples .
Microarray CGH
Samples and reference male DNAs were amplified using the SurePlex whole genome amplification kit (BlueGnome) according to the manufacturer's instructions. Around 3 mg of amplified DNA for samples and reference were labelled using Cy3 and Cy5, respectively, by using the fluorescent labelling system (BlueGnome) following the manufacturer's protocol. The labelling time was 3 h. Labelled sample and reference DNAs were applied to microarrays (24Sure Version 2.0 or high resolution CytoChip Version 3.0) and co-hybridized overnight. Microarray slides were then washed for 10 min in 2× saline sodium citrate (SSC)/0.05% Tween-20 at room temperature followed by 10 min in 1× SSC at room temperature. Slides were further washed for 5 min in 0.1× SSC at 598C and finally for 1 min at room temperature in the same solution. Microarray slides were dried in the vacuum centrifuge at room temperature for 3 min and then scanned. Images were then analysed using Bluefuse Software (BlueGnome), revealing chromosome losses and gains (an aberration was reported if 15 or more probes exhibited deviation from the normal limits on the CytoChip Version 3.0 platform). Published values for the accuracy rate for aCGH are 98 and 95% for blastomeres and TEs, respectively. Errors are attributable to chromosomal mosaicism, which is common in preimplantation embryos Gutiérrez-Mateo et al., 2010) . Microarray-CGH was able to detect aneuploidies in blastocyst biopsies when a third or more of the biopsied cells carried the abnormality .
Results
Five of the 61 samples amplified by Sureplex (to be tested by aCGH) failed to amplify (91.8% efficiency), while 6 of 71 samples amplified by DOP-PCR (to be tested by conventional CGH) failed to amplify (91.5% efficiency). Both aCGH and CGH were successful on all occasions where amplified DNA had been obtained (see Figs 1 and 2 for examples). Overall, results were obtained for 121 of 132 samples (91.7% efficiency).
Of the diagnosed samples, 77.7% were found to be chromosomally abnormal (94/121). Patient's details including maternal age, karyotype of the rearrangement carrier, number of cycles with genetic testing, plus additional clinical factors of potential relevance are described in Table I . The type of cells tested is also listed.
Four of the 16 couples had no normal embryos after diagnosis, while the other 12 couples had at least one normal embryo (after one or two cycles). The method used to test samples and the clinical outcomes are summarized in Table I . The number of normal and abnormal embryos and the predicted karyotype for each embryo is given in Table II .
Of the embryos, 26 had abnormalities affecting only the chromosomes involved in the rearrangement (21.5%). Another 33 (27.3%) had abnormalities affecting chromosomes involved in the rearrangement in addition to other unrelated aneuploidies. There were 35 (28.9%) embryos that were normal/balanced for the rearranged chromosomes, but were abnormal due to aneuploidy affecting other chromosomes. Only 22.3% (27/121) of embryos tested were normal for all chromosomes (Fig. 3) For case four, carrier of inversion (5)(p13.1q13.3), the screening was performed without knowing that there was a rearrangement on chromosome 5. After detecting three embryos affected by structural abnormalities on chromosome 5, we investigated further and were informed by the IVF clinic of the presence of the inversion.
Follow-up data were available for 23 of the embryos originally tested using CGH or aCGH. These embryos were not transferred because a chromosome abnormality had been detected or due to developmental arrest during culture. In each case, the whole embryo was spread on a microscope slide and subjected to confirmatory FISH analysis of the chromosomes involved in the rearrangement, plus chromosomes 13, 16, 18, 21 and 22 (MultiVysion PB, Abbott, IL, USA), using methods we have described previously . The data from these embryos are presented in Table III . Although chromosomal mosaicism was observed in the majority of embryos on Day 4 or 5, this did not lead to any misdiagnoses. All embryos diagnosed abnormal during the initial diagnosis were confirmed as such on follow-up.
Of the 15 patients who have completed their treatment cycles, 5 became pregnant after one or two cycles (33.3%), with the first births occurring in the second half of 2008. One patient is still awaiting embryo transfer after vitrification of blastocysts following biopsy. Out of the 19 completed cycles, 7 (36.8%) had no normal embryos and therefore no transfer was performed. A single cycle had one normal embryo detected, but no transfer due to developmental arrest. Seven cycles (36.8%) had a transfer of normal/balanced embryos, without a pregnancy being achieved. Five cycles (26.3%) achieved a Abnormalities involving the chromosomes involved in the rearrangement are shown in bold typeface. Table S1 containing the ISCN nomenclature of the abnormalities detected can be found in Supplementary data. pregnancy, of which one was biochemical, while four have resulted in healthy births. In one case, a pregnancy was achieved after transfer of an undiagnosed embryo. In this instance, 11 out of 14 embryos were clearly abnormal (confirmed by follow-up analysis). No normal embryos were identified, but three embryos did not receive a diagnosis. After counselling concerning risks, the patient chose to have a single undiagnosed embryo transferred.
Discussion
Performance of aCGH and CGH applied to PBs, blastomeres and TEs
To our knowledge, this is the first study describing the clinical application of comprehensive chromosome screening applied to PBs, blastomeres and TEs from patients carrying chromosome rearrangements. The overall diagnostic efficiencies of conventional (metaphase) CGH and aCGH were very similar, with respectively 91.8 and 91.5% of samples tested yielding a result. These figures are roughly equivalent to the diagnostic success rates achieved by experienced PGD laboratories using established FISH methods (92.9-93.5%) (Munné et al., 2000; Lim et al., 2008; Lledo et al., 2010) and are similar to our experience using CGH and aCGH for the purpose of PGS. We have now tested .1000 oocytes and embryos with aCGH during PGS cycles and our results indicate a diagnostic efficiency for PBs, blastomeres and trophectoderm biopsies of 90.8, 94 and 96%, respectively. For conventional CGH, efficiencies obtained have been similar: 87% for PBs and 93.2% for trophectoderm biopsies (we do not routinely use conventional CGH for blastomere analysis). These data indicate that the new chromosome screening methods have satisfactory performance when applied to the various types of material used for PGD. In terms of detecting partial chromosome losses and gains, the sensitivity of CGH has been reported to be 4-5 Mbp (Piper et al., 1995) . However, this falls to 5 -10 Mbp when applied to single cells.
According to the manufacturer, the 24Sure arrays used in the current study (BlueGnome) have a screening resolution at the single cell level of at least 10 Mbp. Higher resolution can be achieved using the CytoChip array, capable of detecting aberrations as small as 2-5 Mbp (depending on where within the genome the aberration is located). The smallest abnormality detected in this study was a 2.8 Mbp gain of material derived from the centromeric region of chromosome 22, detected in Case 17 (sample 7), using a CytoChip Version 3 microarray. Confirmatory analysis of embryos from PGS cycles, where aCGH and CGH have been used, suggest that these methods detect whole-chromosome losses and gains with accuracy rates ranging from 95% to almost 100% depending on the embryonic stage tested Gutiérrez-Mateo et al., 2010) . In the current study, the losses and gains of whole chromosomes and chromosome fragments originally diagnosed in biopsied cells were confirmed in 23/23 embryos for which follow-up data were available.
Although CGH and aCGH performed well regardless of the type of embryonic material tested (PBs, blastomeres and trophectoderm), there is still debate concerning the optimal stage to perform biopsy. In particular, there are questions over the efficacy of Day-3 (blastomere) analysis. Cell biopsy at the cleavage stage involves the removal of a significant proportion of the embryo volume, potentially impacting viability (Cohen et al., 2007) . Additionally, chromosomal mosaicism is common during the first few days following fertilization, which may compromise accuracy. However, since mosaicism affects chromosomes at random, it is statistically unlikely that the rearranged chromosomes will be affected in a particular embryo, and consequently misdiagnoses are expected to be rare. On the other hand, the extension of screening to cover all chromosomes increases the possibility that a mosaic abnormality, involving chromosomes unrelated to the rearrangement, unique to the cell being tested and absent from the rest of the embryo, could be detected and lead to the exclusion of an otherwise normal embryo. Data from the current study confirm that the use of CGH or aCGH reduces the number of embryos available for transfer (half of the embryos Vanneste et al., 2009; Fragouli et al., in press ). In the current study, a follow-up analysis of non-transferred embryos revealed many instances of mosaicism, but importantly there were no false positive or false negative diagnoses in terms of the rearranged chromosomes and all embryos diagnosed as aneuploid for additional chromosomes were confirmed to be abnormal. Nonetheless, it seems probable that mosaicism will occasionally result in the elimination of a potentially viable embryo if PGD is carried out at the cleavage stage. It has been suggested that the simultaneous testing of several cells, achieved using trophectoderm biopsy, mitigates diagnostic problems associated with the phenomenon of mosaicism . The data from the current study are supportive of this viewpoint. Alternatively, the analysis of PBs should also be resistant to errors caused by mosaicism, since any abnormalities detected in the oocyte are expected to be found in all the cells of any resulting embryos.
In one case during this study (Case 4), chromosome analysis was performed for the purpose of PGS, without the diagnostic laboratory being informed that a rearrangement on chromosome 5 was present in one of the parents. The detection of two embryos with partial aneuploidies affecting regions of chromosome 5, an unusual finding, led us to enquire whether the patients had been karyotyped. The referring clinic then confirmed that the mother was a carrier of on inversion on chromosome 5. This case, in which screening was essentially carried out in a blinded fashion, provides further evidence of the ability of CGH to detect partial chromosome deletion/duplication. During the course of routine PGS cases using CGH or aCGH, we have identified a small number of additional patients who generated a surprisingly large number of embryos with defects affecting the same chromosome. We have recommended that these patients, all of whom have experienced recurrent IVF failure, are offered karyotyping to establish whether a chromosome rearrangement is present in their cells. rearrangement produce a high proportion of abnormal embryos, leading to an increased number of cycles having no normal embryos available for transfer. In the current study, one-third of cycles had no euploid embryos detected. In cases where chromosomally normal embryos were detected the pregnancy rates were good, resulting in a pregnancy rate per transfer of 45.5%. Compared with PGD strategies that only assess the chromosomes involved in the rearrangement, screening the entire set of chromosomes increased the proportion of embryos diagnosed abnormal, as some embryos that were normal/balanced for the rearranged chromosomes were found to be affected by unrelated forms of aneuploidy (Fig. 3) . In theory, the detection of these additional aneuploidies is one of the principal advantages of CGH and aCGH over traditional FISH protocols, since spontaneously arising aneuploidy is a major cause of miscarriage and the birth of children with mental retardation in the population as a whole. It is too early to judge whether CGH/ aCGH can truly improve pregnancy and birth outcomes relative to standard FISH methods. Certainly, the pregnancy rate has not been remarkably increased in the current study compared with previous FISH cases [pregnancy rate per cycle was 25% in (Fischer et al., 2010) and 26.4% in this study]. However, it is encouraging that no miscarriages have been recorded so far. Reduction in miscarriage risk is particularly important, as avoiding this problem is one of the main reasons that patients with a chromosome rearrangement request PGD. In many cases, the patients are able to conceive naturally, but choose to undergo an IVF cycle purely so that they can access PGD and avoid repetition of their previous experience.
In summary, comprehensive chromosome screening methods, such as CGH and aCGH, can be successfully applied for the diagnosis of embryos produced by carriers of chromosome rearrangements, providing a single protocol applicable to most patients of this type, eliminating the delays to treatment and expense of developing patient-specific protocols. CGH and aCGH demonstrated excellent reliability and offer advantages over standard PGD strategies using FISH, such as detection of additional de novo chromosome abnormalities unrelated to the rearrangement. We have shown that comprehensive chromosome screening methods can be applied to PBs, blastomeres or trophectoderm biopsies, but additional work is needed to establish which of these represents the optimal strategy for testing.
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Note added in proof
Since writing this paper, patient 13 has achieved a clinical pregnancy following the transfer of a frozen embryo, diagnosed normal/balanced during this study.
